These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 29564139)

  • 1. Pharmaceutical company spending on research and development and promotion in Canada, 2013-2016: a cohort analysis.
    Lexchin J
    J Pharm Policy Pract; 2018; 11():5. PubMed ID: 29564139
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The relation between promotional spending on drugs and their therapeutic gain: a cohort analysis.
    Lexchin J
    CMAJ Open; 2017 Sep; 5(3):E724-E728. PubMed ID: 28912143
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Early achievements of the Danish pharmaceutical industry--8. Lundbeck].
    Grevsen JV; Kirkegaard H; Kruse E; Kruse PR
    Theriaca; 2016; (43):9-61. PubMed ID: 27491172
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association Between Drug Characteristics and Manufacturer Spending on Direct-to-Consumer Advertising.
    DiStefano MJ; Markell JM; Doherty CC; Alexander GC; Anderson GF
    JAMA; 2023 Feb; 329(5):386-392. PubMed ID: 36749334
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of Sales Income and Research and Development Costs for FDA-Approved Cancer Drugs Sold by Originator Drug Companies.
    Tay-Teo K; Ilbawi A; Hill SR
    JAMA Netw Open; 2019 Jan; 2(1):e186875. PubMed ID: 30644967
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Promotion of prescription drugs to consumers and providers, 2001-2010.
    Kornfield R; Donohue J; Berndt ER; Alexander GC
    PLoS One; 2013; 8(3):e55504. PubMed ID: 23469165
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patentees research and development expenditure in Canada.
    Li S; Tomalin A
    J Pharm Pharm Sci; 2002; 5(1):5-11. PubMed ID: 12042113
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Guidelines, editors, pharma and the biological paradigm shift.
    Singh AR; Singh SA
    Mens Sana Monogr; 2007 Jan; 5(1):27-30. PubMed ID: 22058616
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Report raises questions about drug companies advertising budgets.
    AIDS Policy Law; 1999 Aug; 14(14):1, 6. PubMed ID: 11366996
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Research output of the Canadian pharmaceutical industry: where has all the R&D gone?
    Kalant N; Shrier I
    Healthc Policy; 2006 May; 1(4):21-34. PubMed ID: 19305677
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmaceutical promotion in Canada: convince them or confuse them.
    Lexchin J
    Int J Health Serv; 1987; 17(1):77-89. PubMed ID: 3557776
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Complaints about Violations of Voluntary and Pharmaceutical Industry-Run Medicine Promotion Codes in Canada.
    Lexchin J
    Int J Soc Determinants Health Health Serv; 2023 Oct; 53(4):518-527. PubMed ID: 36938584
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Twelve years' experience with direct-to-consumer advertising of prescription drugs in Canada: a cautionary tale.
    Mintzes B; Morgan S; Wright JM
    PLoS One; 2009 May; 4(5):e5699. PubMed ID: 19479084
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmaceutical Industry Off-label Promotion and Self-regulation: A Document Analysis of Off-label Promotion Rulings by the United Kingdom Prescription Medicines Code of Practice Authority 2003-2012.
    Vilhelmsson A; Davis C; Mulinari S
    PLoS Med; 2016 Jan; 13(1):e1001945. PubMed ID: 26812151
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Research and Development Spending to Bring a Single Cancer Drug to Market and Revenues After Approval.
    Prasad V; Mailankody S
    JAMA Intern Med; 2017 Nov; 177(11):1569-1575. PubMed ID: 28892524
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of pharmaceutical promotion on prescribers in Jordan.
    Altawalbeh SM; Ibrahim IA; Al-Shatnawi SF
    Int J Clin Pharm; 2020 Apr; 42(2):744-755. PubMed ID: 32140917
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Direct-to-consumer promotion of prescription drugs. Economic implications for patients, payers and providers.
    Findlay SD
    Pharmacoeconomics; 2001; 19(2):109-19. PubMed ID: 11284378
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Promotion of prescription drugs to consumers.
    Rosenthal MB; Berndt ER; Donohue JM; Frank RG; Epstein AM
    N Engl J Med; 2002 Feb; 346(7):498-505. PubMed ID: 11844852
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Opioid promotion in Canada: A narrative review.
    Lexchin J
    Indian J Med Ethics; 2024; IX(2):135-142. PubMed ID: 38755771
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A statistical analysis of the magnitude and composition of drug promotion in the United States in 1998.
    Ma J; Stafford RS; Cockburn IM; Finkelstein SN
    Clin Ther; 2003 May; 25(5):1503-17. PubMed ID: 12867225
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.